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This article schematically reviews the clinical features, diagnostic approaches to, and toxicological implications of toxic encepha-
lopathy. The review will focus on the most significant occupational causes of toxic encephalopathy. Chronic toxic encephalopathy, 
cerebellar syndrome, parkinsonism, and vascular encephalopathy are commonly encountered clinical syndromes of toxic en-
cephalopathy. Few neurotoxins cause patients to present with pathognomonic neurological syndromes. The symptoms and signs 
of toxic encephalopathy may be mimicked by many psychiatric, metabolic, inflammatory, neoplastic, and degenerative diseases 
of the nervous system. Thus, the importance of good history-taking that considers exposure and a comprehensive neurological 
examination cannot be overemphasized in the diagnosis of toxic encephalopathy. Neuropsychological testing and neuroimaging 
typically play ancillary roles. The recognition of toxic encephalopathy is important because the correct diagnosis of occupational 
disease can prevent others (e.g., workers at the same worksite) from further harm by reducing their exposure to the toxin, and 
also often provides some indication of prognosis. Physicians must therefore be aware of the typical signs and symptoms of toxic 
encephalopathy, and close collaborations between neurologists and occupational physicians are needed to determine whether 
neurological disorders are related to occupational neurotoxin exposure.
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Introduction
Chemicals capable of  damaging the central nervous system 
(CNS) are ubiquitous in the environment, particularly in oc-
cupational settings. Industrial processes are major sources of 
some of  the most well-known neurotoxins. According to the 
United States Environmental Protection Agency, more than 
65,000 commercial chemicals are currently used in the US, 
and 2,000-3,000 new chemicals are added to this list each year 
[1]. We do not know how many neurotoxic chemicals are used 
in industry at present, but an unadventurous estimate might 
suggest more than 1,000 [2]. People may be exposed to these 
neurotoxins due to their occupations, or occasionally at home 
or through other inadvertent mechanisms. 
The CNS is protected from toxic exposure to some extent, 
but it remains vulnerable to the effects of  certain chemicals 
found in the environment. Nonpolar, lipid-soluble substances 
(e.g., organic solvents) gain the easiest access to the CNS, 
where neurons are particularly susceptible due to their high 
lipid contents and metabolic rates. Both gray matter and white 
matter can be easily damaged by lipophilic toxins [3].
The term “toxic encephalopathy” is used to indicate brain 
dysfunction caused by toxic exposure [4]. Toxic encephalopa-
thy includes a spectrum of symptomatology ranging from sub-
clinical deficits to overt clinical disorders. The clinical manifes-
tations of toxic encephalopathy are related to the affected brain 
regions and cell types [4]. This article schematically reviews the 
clinical features, diagnostic approaches to, and toxicological 
implications of  toxic encephalopathy. The review focuses on 
the most significant occupational causes of toxic encephalopa-
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thy, but does not address iatrogenic (pharmaceutical) causes or 
the neurotoxic effects of illicit recreational drugs or alcohol.
Basic Principles of Neurotoxicology
Several basic principles of neurotoxicology are particularly rel-
evant to the understanding of toxic encephalopathy [5,6]. 
First, there is a dose-response relationship in the majority 
of toxic encephalopathies. That is, the higher the level of expo-
sure, the more severe the symptoms. Similarly, the greater the 
duration of exposure, the higher the likelihood of irreversible 
symptoms. In general, neurological symptoms appear only af-
ter the cumulative exposure has reached a threshold. Individual 
susceptibility varies over a limited range, and idiosyncratic reac-
tions seldom occur.
Second, toxic encephalopathy typically manifests as a 
nonfocal or symmetrical neurological syndrome. The presence 
of significant asymmetry, such as weakness or sensory loss of 
only one limb or on only one side of the body should suggest 
an alternate cause. This principle is very useful when evaluat-
ing a patient with a presumed neurotoxic injury. However, 
electrolyte, glucose, and cortisol levels, liver function and renal 
function tests should be used to distinguish toxic encephalopa-
thy from metabolic encephalopathy, which also presents sym-
metrical signs.
Third, there is usually a strong temporal relationship 
between exposure and symptom onset. After acute exposure, 
the immediate symptoms are often a consequence of the physi-
ological effects of the chemical. Maximum symptoms generally 
occur with maximum exposure, and little delay in onset is seen. 
These symptoms typically subside when the chemical is elimi-
nated from the body. However, delayed or persistent neurologi-
cal deficits sometimes occur after toxic exposure. 
Fourth, the nervous system has a limited capability to re-
generate compared to other organs, such as the liver or hemato-
poietic system. Thus, more sequelae persist after the removal of 
a neurotoxic agent, compared to toxic diseases of other organs.
Fifth, multiple neurological syndromes may occur in re-
sponse to a single neurotoxin, depending on the level and dura-
tion of the exposure. For example, acute, high-level exposure to 
carbon disulfide produces psychosis, whereas chronic moderate 
exposure causes atherosclerosis-related health effects [7,8]. 
Sixth, clinical disorders of  the CNS have varying pre-
sentations, often involving a host of  nonspecific symptoms. 
Furthermore, few neurotoxins cause patients to present with 
a pathognomonic neurological syndrome. The symptoms and 
signs of neurotoxin exposure may be mimicked by various psy-
chiatric, metabolic, inflammatory, neoplastic and degenerative 
diseases of  the nervous system [9]. Therefore, it is crucial to 
take a good occupational history and perform a detailed neuro-
logical examination when diagnosing a toxic encephalopathy.
Seventh, asymptomatic toxic encephalopathy may be seen 
in occupational or environmental settings [10]. Neuropsycho-
logical studies have shown that workers in paint manufacturing 
or painting facilities often have subclinical neuropsychological 
deficits [4,11], and recent studies have revealed that asymptom-
atic toxic encephalopathies are a very common phenomenon 
[4]. Subclinical deficits usually recover after the exposure ceas-
es, whereas clinical disorders usually do not recover. 
Eighth, the timing of exposure relative to critical periods 
of  CNS development may explain some of  the variations in 
susceptibility. The many discrete neuronal populations and 
interacting systems of the nervous system develop at variable 
rates throughout the first three decades of life. Toxic exposures 
may exert profound effects when the organism is in a particu-
larly vulnerable stage, resulting in problems that would not 
occur in response to exposures at other stages of life. The most 
prominent example of this phenomenon is the susceptibility of 
infants to lead encephalopathy [12].
Finally, neurotoxins may reduce the functional reserves 
of  the brain, potentially making the cells more vulnerable to 
the effects of aging and leading to accelerated senescence. This 
may explain the observation that in some cases deterioration 
may continue for many years, even after exposure has ceased.
Clinical Syndromes of Toxic 
Encephalopathy
The major clinical syndromes of toxic encephalopathy include 
diffuse acute or chronic toxic encephalopathy, cerebellar syn-
drome, parkinsonism, and vascular encephalopathy [4,13]. 
Various neurotoxins, including heavy metals, organic solvents 
and other chemicals, have been found to be responsible for 
these relatively specific neurological syndromes [8,9].
Acute diffuse toxic encephalopathy
Acute diffuse toxic encephalopathy reflects a global cerebral 
dysfunction of rapid onset (typically days or weeks), and may 
be associated with alterations in the level of consciousness. The 
neurotoxins that produce acute encephalopathy interfere with 
basic cell functions in the brain [4]. Most of these agents gain 
entry because they are highly lipid soluble and can readily dif-
fuse across membranes. The causative agents include organic 
solvents, which can alter cellular membrane function, and some 
gases (e.g., gas anesthetics, carbon monoxide, hydrogen sulfide, 
and cyanide), which can diffusely affect brain function. Heavy 
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metals can also cause acute encephalopathies; this is more 
commonly associated with organic metals (e.g., methyl mer-
cury, tetraethyl lead and organic tin) than with inorganic metals 
(e.g., mercury, lead and tin) [4]. Virtually any organic solvent 
has the potential to produce acute diffuse toxic encephalopathy, 
the clinical manifestations of which depend on the neurotoxin 
and the intensity of  exposure, and can range from mild eu-
phoria with a normal examination, to stupor, seizure, coma, 
and even death. In general, the greater the exposure, the more 
severe the impairment of cerebral function and consciousness. 
The cerebral cortex is more sensitive to these toxins than is the 
brainstem: even when consciousness is lost, brainstem function 
typically remains intact. Diagnosis does not generally present 
a challenge for acute syndromes, because the exposure and 
clinical manifestations are likely to be closely linked in time. 
In patients with severe acute toxic encephalopathy, magnetic 
resonance imaging (MRI) of the brain may show focal areas, 
most commonly bilateral basal ganglia, or diffuse areas of 
edema [14-16]. The treatment of diffuse acute encephalopathy 
is primarily supportive, starting with removal of the exposure 
source. For most of  the neurotoxins that act diffusely on the 
brain, recovery from acute exposure is complete [4].
Chronic toxic encephalopathy (CTE)
CTE usually represents a chronic persistent diffuse injury to the 
brain resulting from cumulative or repeated exposures (often 
over a period of months or years), to solvents or (occasionally) 
heavy metals. The clinical manifestations of  CTE usually in-
volve varying degrees of cognitive impairment [4].
CTE is an established, internationally recognized condi-
tion that results from excessive occupational exposure to sol-
vents via inhalation or skin contact. In 1985, the World Health 
Organization (WHO) published diagnostic criteria for CTE 
caused by exposure to solvents [11,17]. The most recent Inter-
national Classification of Diseases document (no. 10) defines 
CTE [18], and the Diagnostic and Statistical Manual for Men-
tal Disorders, Fourth Edition [19] lists the condition as a form 
of substance-induced persistent dementia.
The severity of CTE is graded as I-III or 1, 2A, 2B, and 3 
[11,17]. Type I CTE and types 1 and 2A CTE include subjec-
tive symptoms relating to memory, concentration, and mood. 
At this stage, clinicians may miss the diagnosis by considering 
these symptoms as a psychiatric issue due to altered mood 
[4]. Type II CTE and type 2B CTE are characterized by ob-
jective evidence of  attention and memory deficits, decreased 
psychomotor function [11], and/or learning deficits [17] on 
neurobehavioral testing. The taking of  detailed occupational 
and medical histories, as well as standardized neurobehavioral 
testing, are the cornerstones of the standard diagnostic process. 
Workers with a history of repeated episodes indicative of acute 
solvent intoxication (e.g., light-headedness, dizziness, headache 
and nausea) over a period of many years; a history of insidious 
onset of attention, memory, and mood problems; and objective 
evidence of impairment on standardized neurobehavioral tests 
(i.e., deficits in attention, memory, learning and/or psychomo-
tor function) should be considered as meeting the diagnostic 
criteria for type II CTE or type 2B CTE. Type III CTE and 
type 3 CTE are often accompanied by neurological deficits and 
neuroradiological findings. This type of CTE often manifests 
clinical features, whereas types I and II show subclinical defi-
cits. The MRI findings in patients with CTE are nonspecific, al-
though there may be slight brain atrophy; MRI findings mainly 
support the differential diagnosis of  CTE by ruling out other 
brain diseases. Thus, non-solvent etiologies should be consid-
ered if  there are major findings on the brain MRI of a patient 
with suspected CTE [20]. Most cases of  CTE are of  type II 
or 2B [21]. The Finnish criteria for CTE usually includes the 
criterion of more than ten years of daily exposure at work [22]. 
Follow-up is also important in diagnosing patients with CTE. 
Subtle changes in mental functioning due to intoxication often 
go unrecognized unless the clinician specifically assesses these 
changes using sophisticated neuropsychological tests [8].
The high index of  suspicion gives clues to diagnosis of 
CTE. The diagnosis of CTE requires a careful clinical assess-
ment that 1) establishes that there is evidence for abnormality, 
mainly on neuropsychological testing; 2) determines that there 
is good evidence of a relationship to exposure to a potentially 
hazardous neurotoxin; and 3) excludes any other underlying 
causes. Specific therapies for CTE are limited. The patient 
should be separated from the neurotoxic exposure as soon as 
possible. Once the toxin has been removed, the reversibility of 
the brain damage will depend on the grade of CTE [4,23].
The important question of  whether CTE can progress 
to the development of  dementia has not yet been answered. 
Increasing evidence suggests that most forms of degenerative 
dementia have a multi-factorial cause involving genetic, biologi-
cal, and chemical factors [13]. Further studies are needed to 
clarify the issue.
Cerebellar syndromes
Gait ataxia, dysarthria, intention tremor, gaze-evoked nys-
tagmus, dysmetria and adiadochokinesia can all result from 
cerebellar dysfunction [13]. Neurotoxin-induced cerebellar syn-
drome, which is a clinical entity that can be differentiated from 
solvent-induced CTE or carbon-disulfide-induced vascular 
encephalopathy [13], is sometimes accompanied by other neu-
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rological findings. If  a patient presents with cerebellar dysfunc-
tion, a detailed history of his or her occupation and neurotoxin 
exposure should be obtained.
Methyl mercury intoxication (Minamata disease) 
Methyl mercury intoxication, known as Minamata disease, 
causes damage to the granule cell layer in the cerebellum, bilat-
eral diffuse cerebellar atrophy, and microscopically diffuse loss 
of the granule cell layer in the cerebellar cortex [24]. The major 
clinical features of  the disease include progressive cerebellar 
ataxia and disturbance of the sensory functions of the cerebral 
cortex. Cerebellar ataxia manifests as gait ataxia, dysarthria, in-
tention tremor, gaze nystagmus, dysmetria and dysdiadochoki-
nesia. In addition, injuries to the somatosensory, visual, audito-
ry or olfactory cortexes of the cerebrum can manifest as visual 
impairment, hearing impairment, olfactory problems, gusta-
tory disturbance and cerebral cortex-related somatosensory 
disturbances [24]. Concentric constrictions of the visual fields 
are characteristic findings due to damage to the calcarine cor-
tex [13]. In Minamata disease, atrophy of the visual calcarine 
cortex and the cerebellum has been demonstrated on computed 
tomography (CT) and MRI [25-27], and significantly decreased 
blood flow has been shown in the cerebellum on single-photon 
emission computed tomography (SPECT) [27]. Fetal Minama-
ta disease is a typical congenital toxic encephalopathy. Serious 
disturbances in mental and motor development are observed 
in all cases of  fetal Minamata disease. Affected individuals 
show significant bilateral impairments in chewing, swallowing, 
speech, gait, other coordination and involuntary movement 
such as dystonia. These symptoms have been associated with 
the brain damage that is typical of Minamata disease [28].
Methyl bromide intoxication
Methyl bromide is a highly toxic gas that is used widely as an 
insecticidal fumigant for dry foodstuffs. It can be toxic to both 
the CNS and the peripheral nervous system [29,30]. Most neu-
rological manifestations of methyl bromide intoxication occur 
as a result of inhalation. Chronic exposure can cause peripheral 
polyneuropathy, optic neuropathy and cerebellar dysfunction, 
sometimes with neuropsychiatric disturbances [29,30]. Typi-
cally, occupational history is vital to the diagnosis of bromide 
intoxication.
Organic tin intoxication
Organic tins, such as the dimethyl and trimethyl compounds, 
are widely used as polyvinyl-chloride stabilizers, catalysts and 
biocides [31]. Selective cerebellar dysfunction is most promi-
nent upon recovery from coma due to acute severe organic tin 
intoxication [31]. It is easy to diagnose acute organic tin intoxi-
cation in patients whose work history and circumstances of ex-
posure are known, and whose signs and symptoms are typical 
and consistent with those reported in the literature. 
A fluid attenuated inversion recovery (FLAIR) MRI taken 
15 days after an acute organic tin intoxication showed extensive 
symmetrical high-signal lesions throughout the white matter 
of the brain, indicating diffuse brain edema [15]. In a follow-
up study three years after an acute organic tin poisoning case, 
brain MRI showed cerebellar atrophy and 18F-fluorodeoxyglu-
cose positron emission tomography (PET)/CT revealed mildly 
decreased metabolic activity in the pons and in both cerebellar 
hemispheres [31].
Parkinsonism
Manganese intoxication (manganism)
Manganism is one of the most typical forms of parkinsonism. 
Chronic excessive exposure to manganese (Mn) can affect the 
globus pallidus, resulting in parkinsonian signs and symptoms, 
sometimes along with psychiatric features called locura man-
ganica or Mn madness. Historically, miners developed psycho-
sis due to exposure to Mn at levels of  up to several hundred 
milligrams per cubic meter [32]. 
The clinical course of  manganism can be divided into 
three stages: at the first stage, patients with manganism usually 
have prodromal neuropsychiatric symptoms such as asthenia, 
apathy, somnolence, irritability, emotional lability, or frank 
psychoses. At the second stage, bradykinetic-rigid parkinsonian 
syndrome with dystonia, which is reversible, presents as the 
main clinical feature [4]. Patients in the last stage are notable 
for aggravation of the signs and symptoms described as above. 
The clinical progression has been found to be irreversible and 
persistent after the cessation of  exposure in some cases [33]. 
Early diagnosis of manganism is therefore important.
The mechanism underlying this response to Mn exposure 
is not yet clear, but it has been suggested that an initial insult 
to the globus pallidus during Mn neurotoxicity can result in in-
creased activity in the subthalamic nucleus, which is normally 
under tonic inhibition by the globus pallidus in the basal gan-
glia circuitry [34]. Diagnosis of classical manganism requires a 
history of occupational Mn exposure, typical neurological find-
ings such as bradykinesia, rigidity and postural instability, and 
the exclusion of other neurological diseases related to the basal 
ganglia, such as Parkinson’s disease (PD), secondary parkin-
sonism due to traumatic, vascular, or iatrogenic damage, and 
atypical parkinsonism syndromes [35].
The differential diagnoses of  this disorder can be sum-
marized using clinical features and neuroimaging data (Table 
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1) [35-37].The pathological lesions caused by manganism are 
typically degenerative lesions of the globus pallidus, sometimes 
with less-frequent and less-severe injuries to the substantia nigra 
(SN). By contrast, in PD the SN is typically involved while the 
pallidostriatal complex is spared [38].
A Mn-induced, bilateral and symmetrical increase in sig-
nal intensity, confined mainly to the globus pallidus and mid-
brain, can be observed on T1-weighted MRI in Mn-exposed in-
dividuals, but no alterations are typically seen on T2-weighted 
MRI or CT scans [39]. Increased signals on T1-weighted MRI 
were observed in both asymptomatic Mn-exposed workers and 
in patients with experimental or occupational Mn poisoning 
[40-42]. However, these increased signal intensities generally re-
solved 6-12 months after the cessation of Mn exposure [42,43]. 
Thus, a high T1 signal on MRI may reflect the target organ 
dose of recent occupational Mn exposure, but may not neces-
sarily reflect manganism in the spectrum of Mn symptomatol-
ogy [44].
At lower exposure levels, less severe, subtle, and preclini-
cal neurobehavioral effects have been widely reported in vari-
ous occupational and environmental settings [45]. Concerns 
have been raised about whether chronic exposure to low levels 
of Mn can induce PD [43,46]. In fact, PD is not a single dis-
ease, but rather a heterogeneous group of  clinically similar 
conditions. It is possible that some individuals diagnosed with 
PD have neurotoxin-related PD that is likely to have been over-
looked because most cases are not attributable to neurotoxin 
exposure. However, future work will be required to clarify 
whether Mn exposure induces PD and/or affects the progress 
of this condition.
Others
Acute carbon monoxide poisoning can result in a delayed ex-
trapyramidal syndrome that begins two to three weeks after 
recovery from the initial exposure. The parkinsonian features 
can be progressive and are associated with symmetrical degen-
eration of the globus pallidus [47]. Abnormalities may be seen 
in brain CT and MRI [48-50]. Carbon monoxide poisoning 
can also result in cognitive impairment and akinetic mutism as-
sociated with subcortical white matter lesions, especially in the 
bifrontal area [48-50]. Parkinsonian features have occasionally 
been associated with methanol [51], carbon disulfide [52], para-
quat and rotenone [53,54], and cyanide poisoning [55].
Vascular encephalopathy
Carbon disulfide poisoning is a highly typical and frequently 
encountered vascular encephalopathy [8,56]. Patients with car-
bon disulfide poisoning exhibit various clinical characteristics, 
including multiple brain infarctions [57-59], peripheral neu-
ropathy [60], coronary heart disease [61], retinopathy including 
microaneurysm of the fundus [62], hypertension [56], glomeru-
losclerosis of the kidney [63], and parkinsonian symptoms [52]. 
These findings indicate that the basic mechanisms underlying 
carbon disulfide poisoning involve atherosclerotic changes in 
blood vessels [56,64]. The clinical manifestations of  vascular 
encephalopathy (e.g., hemiparesis and speech disturbance) 
Table 1. Comparison of the features of manganism and Parkinson’s disease
Feature Manganism Parkinson’s disease
Bradykinesia/rigidity Typical Typical
Symmetry Symmetrical Asymmetrical
Resting tremor Less frequent, mainly intentional tremor More frequent
Dystonia More frequent Less frequent
Gait disturbance More frequent Less frequent
Gait Cock walk Festinating gait
Propensity to fall backward Typical Not typical
Response to L-dopa Poor response Good response
Signal intensities in globus pallidus in T1-weighted MRI Bilaterally increased* Normal
DAT SPECT/fluorodopa PET Normal Markedly decreased
*A negative MRI signal can occur if manganese exposure ceased at least six months previously.
MRI: magnetic resonance imaging , DAT SPECT: dopamine transporter–single-photon-emission computed tomography, PET: positron emission 
tomography. (From reference 35)
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in cases of  chronic carbon disulfide poisoning are similar to 
those observed in patients with atherosclerotic cerebrovascular 
disorders [56,59]. Many patients presenting with acute cerebro-
vascular stroke-like symptoms, sometimes with hypertension 
or diabetes, have been misdiagnosed as having suffered cere-
brovascular attacks. Thus, the possibility of  carbon disulfide 
poisoning must not be overlooked when physicians make dif-
ferential diagnoses in patients with vascular encephalopathy.
Historical records of carbon disulfide poisoning in Japan 
suggest the presence of a dose-response relationship. Psychosis 
and peripheral neuropathy due to carbon disulfide poisoning 
among rayon industry workers were first reported in 1932 and 
1934, respectively [65]. In the 1930s, when the Japanese first 
began producing rayon, carbon disulfide poisoning was the 
most common occupational disease in Japan [66], and psycho-
sis resulting from very high exposure was a predominant health 
problem. Since 1949, rayon manufacturers have collaborated 
with university researchers in Japan to control carbon disulfide 
concentrations in the workplace and to monitor the incidence 
of carbon disulfide poisoning [66]. By the 1960s, atherosclero-
sis (which is associated with moderate exposure levels) became 
the main type of  carbon disulfide poisoning in Japan [66]. 
Since 1980s, similar clinical features (e.g., atherosclerosis) have 
been observed in Korean workers with carbon disulfide poison-
ing, probably due to the transfer of the rayon industries from 
Japan in the 1960s [67].
Neurodegenerative diseases
Amyotrophic lateral sclerosis (ALS)
ALS is a neurodegenerative disease with an annual worldwide 
incidence of 2-4 cases per 100,000 individuals [68]. A few cases 
have been reported in Korea [69]. The association between 
ALS and exposure to solvents or lead is unclear, and even the 
best-designed incidence studies have produced conflicting re-
sults [70,71].
Other neurodegenerative diseases
It is reported that exposure to solvents, aluminum, mercury, or 
pesticides is implicated in the development of Alzheimer’s dis-
ease, which is the most common neurodegenerative disease [2]. 
However, evidence for this causal relationship is limited and 
further studies are required. PD was dealt with in the mangan-
ism section above.
Diagnostic Approaches for Toxic 
Encephalopathy
A diagnosis of  toxic encephalopathy can be made after 
documentation of  the following: 1) a sufficiently intense or 
prolonged exposure to the neurotoxin; 2) a neurological syn-
drome appropriate for the putative neurotoxins; 3) evolution of 
symptoms and signs over a compatible temporal course; and 4) 
exclusion of other neurological disorders that may account for 
a similar syndrome [6].
The exposure history, physical examination, neurological 
examination, and additional laboratory and radiological studies 
are particularly important for diagnosing a toxic encephalopa-
thy. An overt toxic encephalopathy is not difficult to recognize 
if  a patient develops a well-described clinical syndrome after 
exposure to a well-known neurotoxin, or if  other workers at the 
same site develop similar clinical pictures. The more difficult 
(and more common) situation is when a symptomatic individu-
al presents with either an unclear history of exposure or an ap-
parently trivial exposure to a known or suspected neurotoxin. 
In this situation, careful evaluation of the case is essential [5].
Acquisition of a detailed exposure history 
The patient’s exposure history is central to an accurate clinical 
diagnosis. Many problems can be overlooked or misdiagnosed 
because the person has not been questioned about his or her 
job and its related hazards. The occupational history should 
include information about the person’s current occupation, job 
task, place of  employment, and dates of  attendance on that 
job [72]. Exposure data such as workplace airborne concentra-
tions are crucial. A detailed evaluation of the nature, duration, 
and intensity of the exposure is essential for every evaluation. 
A description of the availability and use of personal protective 
equipment will provide further information about the extent of 
possible exposure. It is also important to ask questions about 
hobbies, and inadvertent exposure from any source should be 
considered [72]. For the diagnosis of toxic encephalopathy, it is 
likely to be helpful if  information on similar problems observed 
in others at the worksite is available.
Neurological examination
After a careful history is obtained, clinical examination should 
be carried out to establish the type and degree of dysfunction. 
The physical examination should include a general examina-
tion followed by a detailed neurological examination. Non-
neurological signs may be a clue to toxic exposure; examples 
of systemic clues include blue gums in lead intoxication, Mees’ 
lines in arsenic poisoning, and acrodynia in mercury poison-
ing [3]. The neurological examination will generally comprise 
assessment of  mental function (mental status examination), 
cranial nerve function, muscle strength and tone, reflexes (mus-
cle stretch and cutaneous), sensation, station and gait [5]. A 
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complete and rigorous neurological examination is necessary 
to properly define the clinical neurological syndrome involved. 
Once defined, a differential diagnosis can be entertained, and 
occupational versus non-occupation or toxic versus non-toxic 
causes can be determined. 
Clinical laboratories
When a patient is seen close to the time of exposure it may be 
possible to measure the offending chemical such as lead and 
mercury or its metabolite in blood or urine. Biomarkers can 
demonstrate that there has been exposure to the relevant toxin 
and that the exposure was of  sufficiently severity to give rise 
to a clinical syndrome. It is obligatory in those cases in which 
there is an acute illness in relation to exposure. However, prob-
lems will undoubtedly occur in those cases where there is a 
delay between exposure and the development of clinical symp-
toms. Furthermore, for most neurotoxins biomarkers are not 
readily available [4,13]. 
There may be occasionally be paraclincal features in 
hematological and biochemical tests indicating red blood cell 
changes as in the case of lead poisoning, or liver function test 
abnormalities as in the case of some organic solvent poisoning. 
For most of neurotoxins, however, clinical laboratory tests are 
not helpful for diagnosis [4,13].
Neurobehavioral testing
Neurobehavioral (neuropsychological) testing, which is an 
accepted methodology for assessing the functional integrity 
of the CNS, has been used extensively to evaluate subclinical 
neurotoxic effects on cognition, memory, alertness, executive 
function, mood and psychomotor skills [73-75]. There is a wide 
spectrum of neuropsychological tests, and the selection must be 
tailored to each situation. Neurobehavioral testing is generally 
administered by an examiner, as in the Neurobehavioral Core 
Test Battery from the WHO [73]. Recently, however, many of 
the tests have been adapted for use on a personal computer. In 
toxic encephalopathy due to various neurotoxins (e.g., heavy 
metals or organic solvents), neuropsychological studies have 
been useful in evaluating subclinical findings [45,75,76]. In-
deed, since the 1990s, subclinical neuropsychological deficits 
detected by neurobehavioral testing have replaced overt clinical 
findings as the basis of occupational exposure limits for various 
neurotoxicants [44,77]. Neurobehavioral tests are also used as 
diagnostic criteria for CTE. 
Electroencephalography (EEG)
EEG, which records the electric activity of the brain, has been 
used to evaluate occupational neurotoxic exposures [78,79]. 
The changes that are most obvious on EEG, such as diffuse 
slowing, are often associated with toxic encephalopathy [4]. 
However, the observed abnormalities are not specific, meaning 
that EEG has only a limited value in detecting and charac-
terizing toxic encephalopathy [9]. With the advent of  recent 
technological advances in neuroimaging, EEG is now used 
less frequently as a neurodiagnostic method, and more often in 
evaluating epilepsy. 
Evoked potentials (EVPs)
Sensory EVPs are widely used in clinical neurology as an index 
of  the integrity of  the sensory CNS pathways. Compared to 
EEG, EVPs can provide more quantitative information and 
can be used to assess a sensory pathway from the receptor to 
the cortex. Among the EVPs, the visual evoked potential (VEP), 
auditory evoked potential (AEP), and somatosensory evoked 
potential (SEP) are most often used in evaluating neurotoxic 
disease and other neurological disorders [79]. However, many 
variables can confound interpretation, and the results are not 
specific to neurotoxic disease [4] and thus should be interpreted 
with caution [80]. Marked AEP abnormalities have been as-
sociated with toluene exposure [81,82], but these studies were 
performed in toluene abusers, who are exposed to much higher 
levels than those usually found in occupational settings.
Neuroimaging studies
Since the invention of  CT and MRI scanners, tremendous 
progress has been made in the medical imaging of the human 
body. Neuroimaging can be divided into two groups: morpho-
logical neuroimaging (anatomy-based imaging) such as CT and 
MRI, and functional neuroimaging (physiology-based imaging) 
such as magnetic resonance spectroscopy (MRS), functional 
MRI, diffusion tensor imaging (DTI), SPECT, and PET. At 
present, with the introduction of  new technologies and the 
solving of technical problems related to the local production of 
radioisotopes, neuroimaging is shifting from morphological to 
functional [83,84].
CT
Modern CT scanners are capable of performing multiple slices 
with rapid data acquisition and overlapping sections using con-
tinuously moving X-ray emitters (spiral CT). These methods 
enable the rapid production of  exquisite images with three-
dimensional reconstruction capabilities. In the brain, the use of 
X-ray contrast agents and angiography has improved intracra-
nial imaging, but CT remains almost exclusively an anatomical 
imaging tool [83-86]. In terms of neurotoxin-related damage, 
CT is valuable for ruling out other naturally occurring disorders 
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of the nervous system, and it can reveal nonspecific changes 
(e.g., cortical atrophy) in individuals chronically exposed to or-
ganic solvents in the workplace [87].
MRI
MRI provides images that enhance either the fatty component 
(so-called ‘T1-weighted’ images) or the water component (so-
called ‘T2-weighted’ images) of tissues. It has emerged as the 
pre-eminent imaging modality for visualizing neurological 
diseases in the central nervous system, because it can distin-
guish gray and white matter, zones of  demyelination, and 
brain edema [83,88]. The distinction between gray and white 
matter lesions is crucial because gray matter is more vulner-
able to anoxic or ischemic insults due to its higher metabolic 
demands for oxygen and glucose [89]. White matter changes, 
such as leukoencephalopathy, are usually better seen on MRI, 
whereas calcifications and hemorrhages are readily detectable 
by CT. However, the severity and extension of brain lesions on 
morphological neuroimaging do not necessarily match the se-
verity of clinical status [89]. T1-weighted MRI can detect para-
magnetic metals, such as Mn, making it uniquely useful in Mn 
neurotoxicology. On T1-weighted MRI, Mn exposure causes 
bilateral symmetrical increases in signal intensity that are con-
fined to the globus pallidus and midbrain [39-41,46]. 
MRS
Numerous whole-body MR scanners now operate at magnetic 
fields of 1.5 Tesla (T) or above, meaning that they can perform 
localized proton MRS without additional hardware [90]. The 
latest very-high-field strength (i.e., 3 T or more) MRI systems 
generate images that combine anatomical and physiological 
measurements. In vivo proton magnetic resonance spectroscopy 
([1H]-MRS) is an image-guided, noninvasive method for moni-
toring neurochemical metabolites in the brain [90]. Currently, 
[1H]-MRS is most commonly employed to obtain metabolic 
information that may aid in the diagnosis of many neurologi-
cal diseases, and also allows the evaluation of disease progres-
sion and treatment response [91]. Although MRS permits 
noninvasive in vivo measurement of brain metabolites, only a 
few MRS investigations have assessed the neurological effects 
of neurotoxins in environmental or occupational health. Aydin 
et al. [92] demonstrated decreased N-acetylaspartate (NAA) in 
the cerebellar white matter and centrum semiovale along with 
increased myoinositol (mI) in toluene abusers. Several recent 
reports have analyzed the impact of lead exposure on brain me-
tabolism in vivo in adults and children [93-96], while two other 
studies employed MRS to investigate the potential neurotoxic 
effects of  chronic Mn exposure on the brain [97,98]. In par-
ticular, Guilarte et al. [97] assessed the toxic effects of chronic 
Mn exposure on the levels of brain metabolites in non-human 
primates. This [1H]-MRS study found that the NAA/creatine 
(NAA/Cr) ratios in the parietal cortex and frontal white matter 
were decreased after Mn exposure, indicating ongoing neuro-
nal degeneration or dysfunction. NAA is known to serve as 
a neuronal marker [99], and a reduction in brain NAA levels 
can be interpreted as indicating neuronal dysfunction or loss 
[100]. However, Kim et al. [98] found no significant difference 
between welders and control subjects in this measure. Similarly, 
Chang et al. [101] recently showed that the NAA/Cr ratios in 
both the anterior cingulate cortex and parietal white matter did 
not differ significantly between welders and controls. However, 
they found that the mI levels in the anterior cingulate cortex, 
but not in the parietal white matter, were significantly lower in 
welders compared with control individuals. Furthermore, in 
the frontal lobe of the brain, the mI/Cr ratio was significantly 
correlated with verbal memory scores and blood Mn concen-
trations. This study therefore suggested that the depletion of 
mI in welders may reflect a possible glial cell effect (rather than 
a neuronal effect) associated with long-term exposure to Mn. 
More recently, Dydak et al. [102] used the MEGA-PRESS 
sequence to determine γ-aminobutyric acid (GABA) levels in 
the thalamus, and found that Mn-exposed subjects showed 
significant decreases in the NAA/Cr ratio of the frontal cortex, 
and significant increases in the GABA level of  the thalamus. 
Further MRS-based studies will be required to fully assess the 
various brain metabolites in Mn-exposed workers. 
Functional MRI
Functional MRI (fMRI) uses standard clinical MRI hardware 
to collect information regarding brain metabolism changes as-
sociated with neuronal activity. As neuronal activity and the 
resulting demand for oxygen increase, the supply of  oxygen-
ated hemoglobin correspondingly increases, along with the 
MR signal measured on T2* images. This generates blood-
oxygenation-level-dependent (BOLD) contrasts [103].
The use of  fMRI to study neurological diseases has be-
come much more common over the last decade, but employ-
ing fMRI to assess neurotoxicity in humans is a rather novel 
approach. There have not yet been any reports on functional 
MRI findings in metal neurotoxicity. Chang et al. [104] were 
the first to use fMRI and sequential finger-tapping to investi-
gate the behavioral significance of additionally recruited brain 
regions in welders who had experienced chronic Mn exposure. 
Their findings suggest that fMRI may help us uncover evidence 
of  compromised brain functioning in patients with subclini-
cal manganism. The observation that the cortical motor net-
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work was excessively recruited in the chronically Mn-exposed 
group is in line with the emerging concept that adaptive neural 
mechanisms are used to compensate for latent dysfunctions in 
the basal ganglia. Chang et al. [105] also combined fMRI with 
two-back memory tests to assess the neural correlates of Mn-
induced memory impairment in response to subclinical dys-
function in the working memory networks of welders exposed 
to Mn for extended periods of time. These fMRI findings indi-
cated that welders might need to recruit more neural resources 
to their working memory networks in order to compensate 
for subtle working memory deficits and alterations in working 
memory processes.
DTI 
DTI, which is a unique method for characterizing white matter 
micro-integrity [106], can reveal the orientation of white mat-
ter tracts in vivo and yields indices of microstructural integrity 
by quantifying the directionality of water diffusion [107,108]. 
A few previous studies have explored the toxic encephalopathy 
associated with exposure to environmental neurotoxins, such 
as mercury [109], Mn [110], methanol [111], and carbon mon-
oxide [112] using diffusion-weighted image (DWI) analysis. 
However, few studies have reported DTI-detected alterations of 
microscopic integrity within the white matter of subjects expe-
riencing environmental neurotoxic exposure [113]. Kim et al. 
[114] used DTI to investigate whether welders exposed to Mn 
exhibited differences in white matter integrity. White matter 
microstructural abnormalities (decreased fractional anisotropy 
[FA]), which correlated with deficits in motor and cognitive 
neurobehavioral performance, were observed in welders, as 
compared to controls.
SPECT
SPECT is a widely distributed functional imaging modality 
that is more easily accessible and less expensive than PET, but 
has a lower resolution [39]. SPECT allows the imaging of re-
gional blood flow, metabolism and neurotransmitter receptors 
with relatively good spatial resolution. SPECT of patients with 
Minamata disease showed significantly decreased blood flow 
in the cerebellum [27]. In a case of acute lithium intoxication, 
the CT and MRI were normal, but a SPECT scan indicated 
significant focal perfusion defects, predominantly involving 
the left temporo-parietal area and the right posterior parieto-
occipital area [115]. Huang et al. [116] reported that the stria-
tal 99mTc-TRODAT-1 uptake in dopamine transporter (DAT) 
SPECT was nearly normal in Mn-induced parkinsonism, but 
was markedly reduced in PD. Various ligands that bind to 
DAT, such as [123I]-β-CIT, [123I]-fluoropropyl-CIT and 99mTc-
TRODAT-1, have been used in SPECT studies to elucidate the 
function of the dopaminergic nigrostriatal pathway, and thus to 
differentiate manganism from PD [46,116,117].
PET
PET uses short-lived positron-emitting isotopes to mark bio-
logically active compounds. PET isotopes have such short half-
lives that they must be produced in on-site cyclotrons to be 
available in quantities viable for clinical use. PET relies on a 
visibly labeled ligand to provide image specificity [84,118,119]. 
Specific ligands have been developed to help elucidate the func-
tion of the dopaminergic nigrostriatal pathway. For example, 
the ligand [18F]-dopa provides information about the conver-
sion of L-dopa to dopamine [120]. In nonhuman primates and 
humans with manganism, the [18F]-dopa PET scan (which 
provides an index of the integrity of the dopaminergic nigros-
triatal pathway) is normal [39,121-123]; by contrast, reduced 
dopamine uptake occurs in the striatum and particularly the 
posterior putamen of  PD patients [39,124]. Thus, [18F]-dopa 
PET scans have been used to differentiate manganism from PD 
[46,116,117]. In addition, 18F-fluorodeoxyglucose (18F-FDG) 
PET may be used to show metabolic activity in the brain. 
In a follow-up study of  an acute organic tin poisoning case 
three years after diagnosis, 18F-FDG PET/CT revealed mildly 
decreased metabolic activity in the pons and in both cerebel-
lar hemispheres [31]. Similarly, decreased metabolism in the 
thalamus, basal ganglia, temporal lobe and inferior parietal 
lobe have been observed in hydrogen sulfide poisoning using 
18F-FDG PET [125].
Clinical Implications
Many toxic encephalopathies may go unrecognized. In the 
absence of  a detailed neurological examination and compre-
hensive work history, physicians may overlook the possibility 
of previous or current neurotoxin exposure. The recognition of 
toxic encephalopathy is important for clinicians for several rea-
sons: 1) diagnosis can protect others (e.g., workers at the same 
worksite) from further harm by reducing exposure to the toxin; 
2) diagnosis often provides some indication of prognosis; and 3) 
recognition of neurotoxic exposure can bring about improved 
hygiene measures that may protect other workers.
Physicians must be aware of the typical signs and symp-
toms of toxic encephalopathy, and they should also pay atten-
tion to less typical, rather vague symptoms and signs because 
the toxicological characteristics of  toxic encephalopathy may 
be less typical, particularly in cases of long-term, low-dose ex-
posure, perhaps combined with the effects of aging. Close col-
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laborations between neurologists and occupational physicians 
are needed to determine whether neurological disorders are 
neurotoxin-related.
Summary
CTE, cerebellar syndrome, parkinsonism and vascular en-
cephalopathy are commonly encountered clinical syndromes 
of  toxic encephalopathy. Few neurotoxins cause patients to 
present with pathognomonic neurologic syndromes. The symp-
toms and signs of toxic encephalopathy may be mimicked by 
many psychiatric, metabolic, inflammatory, neoplastic and 
degenerative diseases of the nervous system, so the importance 
of  good history-taking and a comprehensive neurological ex-
amination cannot be overemphasized in the diagnosis of toxic 
encephalopathy. Neuropsychological testing and neuroimaging 
typically play ancillary roles. 
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